RAS Mutation Status and Immune Microenvironment in 225 pMMR Colorectal Cancer Patients

225 patients with proficient mismatch repair (pMMR) colorectal cancer were analyzed to define how K/N-RAS mutational status interacts with the tumor immune microenvironment. Multiplex immunohistochemistry quantified immune cell densities and protein expression, revealing distinct prognostic subtypes and predictive biomarkers for chemotherapy benefit. Author Shigang Wu published this dataset under CC-BY-4.0 license on figshare in May 2026.

Use Cases

• Predicting chemotherapy benefit in pMMR CRC based on RAS mutation status and CD163+ macrophage density.
• Stratifying patient prognosis using stromal CD4+ T-cell infiltration in RAS wild-type tumors.
• Identifying poor survival risk groups based on intraepithelial CD8+ T-cell loss and CD163+ macrophage density in RAS-mutant tumors.
• Investigating the interplay between β-catenin, CMTM6, and PD-L1 expression with immune cell infiltration.

Strengths

• Includes data from 225 patient records, providing a substantial cohort for analysis.
• Multiplex immunohistochemistry was used to quantify specific immune cell types (CD4+, CD8+, CD68+, CD163+) and protein expression.
• Multivariable Cox regression and formal interaction testing were performed, suggesting robust statistical analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is retrospective and from a single study, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective analysis of patient samples using multiplex immunohistochemistry.

Freshness

Last updated 2026-05-07 04:45:32; freshness should be verified.